Milestone Alert: First Patient Dosed in Phase 3 Study of YCANTH for Common Warts
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A phase 3 study of a treatment for common warts has dosed its first patient. The treatment being studied is called YCANTH, although some reports suggest it may be part of a second phase 3 trial. It is unclear if this is the only phase 3 study of YCANTH for common warts, as other outlets are reporting on different clinical trials for various conditions and treatments.
Full coverage
1
The Dermatology Digest·Jun 232
CGTLive®·Jul 73
The Manila Times·1d ago4
Ophthalmology Times Europe·Jun 225The Dermatology Digest·Apr 296
EurekAlert!·Feb 37CGTLive®·Jul 98
Business Wire·Apr 8